Navigation Links
Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease
Date:7/1/2009

EXTON, Penn., July 1 /PRNewswire/ -- Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, announced a research collaboration agreement with Synageva BioPharma Corporation to express and develop therapeutic monoclonal antibodies for the potential treatment of various forms of cancer and infectious disease.

Under the terms of the agreement, Synageva will use its proprietary Synageva Expression Platform (SEP(TM)) technology and its expertise to produce and develop a therapeutic monoclonal antibody. SEP(TM) is an integrated platform of proprietary systems for protein production, processing and purification.

"Morphotek is an industry leader in antibody discovery and development," said Sanj K. Patel, President and Chief Executive Officer of Synageva BioPharma Corporation. "Their commitment to utilizing Synageva's platform is a testament to the strength of our science and product development capabilities and we are excited about the potential for this collaboration."

"We have a rich pipeline of antibody products such as MORAb-003, or farletuzumab, for ovarian cancer in Phase III, MORAb-009 for pancreatic cancer in Phase II and MORAb-004 that is pan-cancer specific in Phase I," stated Philip M. Sass, PhD, Executive Vice President and Chief Operating Officer, Morphotek, Inc. "We are always exploring new ways that may enhance the manufacturing process for our antibody products as a means to fulfill Eisai's hhc mission."

Through the use of its proprietary MORPHODOMA(R) technology, Morphotek develops optimized antibodies, including antibodies optimized for affinity and/or titer, for therapeutic applications and high-titer manufacturing cell lines. The company has assembled a portfolio of lead human and humanized antibodies to antigens associated with cancer, neovascular, inflammatory and infectious disease. The antibodies within the company's pipeline are targeted against a
'/>"/>

SOURCE Morphotek, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Morphotek(R), Inc. Announces Initiation of MORAb-009 Phase II Study in First- Line Treatment of Mesothelioma
2. Human Genome Sciences and Morphotek(R), Inc. Announce Collaboration to Discover, Develop and Commercialize Antibodies for Oncology and Immunology
3. Morphotek(R), Inc and Lonza Group Ltd Enter Into Manufacturing Services Agreement
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
6. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
7. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
8. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
9. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... (PRWEB) January 14, 2014 iLab Solutions, the ... as the new Director of Product Strategy. In this role, ... as iLab sub-teams to guide in the development of iLab ... provides the maximum possible benefit to the scientific community by ...
(Date:1/14/2014)... MD (PRWEB) January 14, 2014 ... to developing innovative information technology solutions for patients, ... health care stakeholders, announced today the signing of ... US Food and Drug Administration (FDA). This ...
(Date:1/14/2014)... Orange, CA (PRWEB) January 14, 2014 Kerr ... a 10-minute video and additional how-to information about dual arch ... Great Restorations with Dual Arch Impressions,” the blog entry serves ... the technique and houses a step-by-step demonstration by Dr. David ...
(Date:1/14/2014)... BioMedomics, Inc. , a Point of Care ... novel disease specific POC tests, announced today that it has ... of $690,000. The investment is from private investors and is ... of private investors has significant successful experience in early investments ...
Breaking Biology Technology:iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2BioMedomics, Inc. Closes $690K Round of Financing 2
... AMSTERDAM, August 17 SynCo ... Inc. today,announced a strategic partnership to produce Versartis, lead ... to treat type 2 diabetes,Under the agreement, SynCo will ... optimize the manufacturing process to,increase yields for the forthcoming ...
... /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc.,(Nasdaq: CHBT ) ("China-Biotics", "the ... marketing and,distribution of probiotics products, today announced its financial results ... 30, 2009. , , First Quarter 2010 ... to $15.4 million, -- Gross profit rose ...
... water for granted, that ordinary tap water could become deadly ... School of Physics and Astronomy. To combat the threat ... the physicist has developed a new system to monitor the ... time. Modifying special fibers developed in his Tel ...
Cached Biology Technology:SynCo Bio Partners to Manufacture Versartis Novel Drug for Type 2 Diabetes 2China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 2China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 3China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 4China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 5China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 6China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 7China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 8China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 9China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 10China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 11Monitoring water through a snake's eyes 2Monitoring water through a snake's eyes 3
(Date:7/9/2014)... of studies suggest that children delivered by Caesarean section have ... But it is still unknown why this is the case ... the Faculty of Health and Medical Sciences therefore decided to ... immune system in a study of newborn mouse pups. ... Caesarean section had developed a lower number of cells that ...
(Date:7/9/2014)... switch out one gene for another in a line ... fiction to reality within this decade. As with any ... of fixing disease-causing genes in humans, for example--as well ... put one of those concerns to rest: using gene-editing ... of mutations in the cells. The new results were ...
(Date:7/9/2014)... Ind. - Regulated deer hunts in Indiana state parks ... decades of damage caused by overabundant populations of white-tailed ... led by Michael Jenkins, associate professor of forest ecology, ... policy of organizing hunts in state parks has successfully ... wildflowers rendered scarce by browsing deer. , Jenkins ...
Breaking Biology News(10 mins):Mouse study: Natural birth may strengthen the immune system 2No extra mutations in modified stem cells, study finds 2No extra mutations in modified stem cells, study finds 3Hunting gives deer-damaged forests in state parks a shot at recovery 2
... 2013 AT&T * and NEC Corporation of ... workhorse among ruggedized 4G LTE smartphones , the ... equipped with AT&T Enhanced Push-to-Talk (EPTT)**, NEC ... is aimed at breaking productivity barriers to keep workforces ...
... anabolic agent for tissue-building and energy storage, promoting the ... inhibiting their breakdown and release into the circulatory system. ... entry into muscle tissue, where the glucose is metabolized ... exist in understanding the precise molecular mechanisms by which ...
... YORK , June 19, 2013  New York College of ... States Patent and Trademark Office for detecting biometric changes through ... have been injured, attacked or killed. This patent ... Agreements of New York College of Health Professions. ...
Cached Biology News:AT&T and NEC Introduce Ultra-Rugged Smartphone Designed for Hard Work, Real Life 2AT&T and NEC Introduce Ultra-Rugged Smartphone Designed for Hard Work, Real Life 3AT&T and NEC Introduce Ultra-Rugged Smartphone Designed for Hard Work, Real Life 4AT&T and NEC Introduce Ultra-Rugged Smartphone Designed for Hard Work, Real Life 5Breakthrough research of essential molecule reveals important targets in diabetes and obesity 2New Technology Using Biometrics Detects If Security Guards Are Attacked, Injured Or Killed 2New Technology Using Biometrics Detects If Security Guards Are Attacked, Injured Or Killed 3New Technology Using Biometrics Detects If Security Guards Are Attacked, Injured Or Killed 4
Rb anti-Occludin (C-term GST)...
anti-JNK2 Immunogen: Recombinant human JNK2 protein Accession Number: NM_002752 Quality Assurance: Routinely evaluated by immunoblot. Molecular Weight: 46 and/or 54 kDa Available ...
...
Prepared with distilled water. Yeast extract solution is autolyzed at 150 g/L....
Biology Products: